GLP1R and Hypoglycemia: Incretin mimetics present other favorable properties such as a low hypoglycaemia risk, the ability to address postprandial hyperglycemia (DPP-4 inhibitors and short-acting GLP-1R agonists), and potential for weight reduction (GLP-1R agonists; Neumiller, 2015).